Synlogic finds public route via Mirna, raises $42M

Synthetic biology company Synlogic Inc. (Cambridge, Mass.) will become a publicly traded entity via a reverse merger with Mirna Therapeutics Inc. (NASDAQ:MIRN). The combined company will keep Synlogic's name and develop that company's programs, including one which is due to enter the clinic in mid-2017.

Synlogic also raised $42 million in a series C round led by Aju IB Investment, Ally Bridge Group, Arctic Aurora LifeScience, CLI Ventures, Perceptive Advisors, Rock Springs Capital, and other undisclosed new investors. Also participating were existing investors Atlas Venture, Deerfield, New Enterprise Associates (NEA), and OrbiMed...